Cardiovascular and Venous Thromboembolic Risk With Janus Kinase Inhibitors in Immune‐Mediated Inflammatory Diseases: A Systematic Review and Meta‐Analysis of Randomized Trials

OBJECTIVE: Janus kinase (JAK) inhibition effectively treats immune‐mediated inflammatory diseases (IMIDs); however, concern over the risk of major adverse cardiac events (MACE) and venous thromboembolism (VTE) remains. We aimed to evaluate the safety (VTE and MACE outcomes) of JAK inhibitors in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Maqsood, Muhammad Haisum, Weber, Brittany N., Haberman, Rebecca H., Lo Sicco, Kristen I., Bangalore, Sripal, Garshick, Michael S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555201/
https://www.ncbi.nlm.nih.gov/pubmed/35903881
http://dx.doi.org/10.1002/acr2.11479

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555201/
https://www.ncbi.nlm.nih.gov/pubmed/35903881
http://dx.doi.org/10.1002/acr2.11479

Ejemplares similares